利用海洋资源用于阿尔茨海默氏症治疗:综合生物活性和分子对接的审查
Hina Khalid1, Hassan Mohamed2, Adel Eltoukhy2
1Colin Ratledge Center of Microbial Lipids, School of Agricultural Engineering and Food Science, Shandong University of Technology, Zibo, 255000, China.
European journal of pharmacology
|April 11, 2025
概括
海洋化合物为阿尔茨海默病 (AD) 治疗提供了一个有希望的,可持续的方法,通过向粉样蛋白β (Aβ) 斑块形成和减少氧化应激. 这些天然化合物表现出神经保护作用,可能克服当前针对Aβ治疗的局限性.
科学领域:
- 神经科学是一个神经科学.
- 海洋生物学 海洋生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏病 (AD) 的特点是神经纤维状结和粉样β (Aβ) 斑块.
- 目前针对Aβ的治疗方法在临床试验和疾病干预方面存在局限性.
- Aβ蛋白的积累是AD病理学的关键驱动因素.
研究的目的:
- 审查海洋化合物在阿尔茨海默病治疗中的潜力.
- 探索隔离和提取机制,以优化海洋衍生疗法.
- 研究海洋天然产品 (MNP) 的神经保护机制.
主要方法:
- 关于海洋化合物和AD的综合文献综述.
- 关键的海洋化合物与Beta-secretase受体的基分子对接.
- 对隔离和提取方法的分析,重点是绿色化学和可持续性.
主要成果:
- 海洋水产养殖的副产品是潜在的AD治疗的可持续来源.
- 海洋天然产品 (MNPs) 具有神经保护作用.
- MNPs可以最大限度地减少Aβ的形成和反应性氧物种 (ROS) 的产生.
结论:
- 海洋化合物代表了阿尔茨海默病的有希望的治疗途径.
- 可持续采购和绿色提取方法提高了来自海洋的药物的可行性.
- MNPs提供了一种新的策略,以抑制AD的关键病理事件.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
400
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.5K
相关概念视频
01:22Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
01:26Alzheimer's Disease: Overview
336
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336